Nureca
Nureca (NURECA) share price was ₹300.50 at the 28 Oct 2026 close; market capitalisation ₹287 Cr; P/E (TTM) 68.61; sector Healthcare. The share price rose 4.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 18.0% year on year to ₹40.34 Cr and net profit was ₹3.07 Cr, against ₹0.81 Cr a year earlier (compared with Jun 2025). Promoters held 70.68% of Nureca in Sep 2026, up 2.59 percentage points from Jun 2026. Its Tapetide Score is 55/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapHealthcare Equipment & SuppliesHealthcarePrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Medical Equipment › Medical Equipment & Supplies
| ₹1,476.00 | 47.48 | 14,961 Cr | 4.82 | 0.24% | 10.18% | 13.33% | 2,115 Cr | 313 Cr | |
| ₹26.66 | 70.16 | 1,745 Cr | 3.81 | 0.20% | 8.11% | 12.69% | 373 Cr | 24 Cr | |
| ₹304.60 | 145.74 | 1,621 Cr | 2.55 | 0.66% | 2.26% | 4.82% | 468 Cr | 11 Cr | |
| ₹544.45 | 25.80 | 1,270 Cr | 2.60 | 0.00% | 22.63% | 26.37% | 201 Cr | 34 Cr | |
| ₹181.39 | 32.33 | 998 Cr | 4.10 | 0.00% | 10.83% | 11.51% | 289 Cr | 31 Cr | |
| ₹572.55 | — | 832 Cr | 5.31 | 0.00% | 13.22% | 19.52% | — | — | |
| Nureca (this company) | ₹300.50 | 68.61 | 287 Cr | 1.53 | 1.01% | 1.15% | 3.43% | 180 Cr | 4 Cr |
| Median 7 companies | ₹304.60 | 58.05 | 1,270 Cr | 3.81 | 0.20% | 10.18% | 12.69% | 331 Cr | 28 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Promoter holding has increased by 2.59% over last quarter.
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -7.19% over past five years.
- Company has a low return on equity of -0.56% over last 3 years.
- Earnings include an other income of Rs.7.35 Cr.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 8.48% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.23 | 31.35 | 22.37 | 16.97 | 20.27 | 31.19 | 26.46 | 31.74 | 34.18 | 37.74 | 39.64 | 35.41 | 40.34 |
| Expenses | 24.13 | 29.97 | 26.62 | 21.4 | 22.63 | 33.54 | 30.47 | 30.54 | 34.74 | 34.47 | 36.39 | 41.19 | 36.92 |
| Operating Profit | -2.9 | 1.38 | -4.25 | -4.43 | -2.36 | -2.35 | -4.01 | 1.2 | -0.56 | 3.27 | 3.25 | -5.78 | 3.42 |
| OPM % | -13.66% | 4.4% | -19% | -26.1% | -11.64% | -7.53% | -15.15% | 3.78% | -1.64% | 8.66% | 8.2% | -16.32% | 8.48% |
| Other Income | 2.67 | 3.2 | 5.9 | -1.26 | 5.79 | 3.17 | 1.48 | 1.99 | 2.57 | 2.32 | 2.19 | 1.02 | 1.82 |
| Interest | 0.12 | 0.08 | 0.11 | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 | 0.3 | 0.2 |
| Depreciation | 0.58 | 0.59 | 0.59 | 0.6 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.5 | 0.45 | 0.61 |
| PBT | -0.93 | 3.91 | 0.95 | -6.47 | 2.62 | -0.07 | -3.25 | 2.05 | 1.23 | 4.59 | 4.66 | -5.51 | 4.43 |
| Tax % | -23.66% | 25.83% | 82.11% | -35.86% | 36.64% | 585.71% | -13.85% | -20% | 34.15% | 21.13% | 19.96% | 10.71% | 30.93% |
| Net Profit | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.8 | 2.47 | 0.81 | 3.63 | 3.73 | -6.09 | 3.07 |
| EPS (₹) | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.8 | 2.47 | 0.81 | 3.63 | 3.91 | -6.38 | 3.22 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | 153 |
| Expenses | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | 149 |
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 0 | 4 |
| OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | 0.1% | 2.7% |
| Other Income | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 8 | 7 |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| PBT | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 5 | 8 |
| Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | 58% | — |
| Net Profit | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 2 | 4 |
| EPS (₹) | 623 | 640 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 | 4.38 |
| Div. Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 171 |
| Borrowings | 0 | 10 | 4 | 4 | 3 | 3 | 5 | 2 |
| Other Liabilities | 15 | 9 | 19 | 12 | 8 | 10 | 11 | 13 |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
| Fixed Assets | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 1 |
| Other Assets | 23 | 33 | 182 | 175 | 139 | 104 | 200 | 182 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 0 | -8 | 35 | 1 | 10 | -3 | -19 | 3 |
| Investing | 0 | 0 | -110 | -3 | -16 | 18 | 8 | 14 |
| Financing | 0 | 8 | 92 | -7 | -2 | -1 | 0 | -20 |
| Net Cash Flow | 0 | 0 | 17 | -9 | -8 | 14 | -11 | -2 |
| Free Cash Flow | 0 | -8 | 34 | -5 | 10 | -4 | -23 | -3 |
| CFO/EBITDA | 4 | -82 | 81 | 35 | -96 | 39 | 234 | 1,464 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 | 19 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 | 187 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 | 20 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 163 | 145 |
| ROCE % | — | 57% | 67% | 33% | -6% | -4% | 1% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nureca insights
60 extracted metrics + investor summaries across FY18–FY27.
Documents
Frequently Asked Questions about Nureca
What does Nureca Ltd do?
Where is Nureca Ltd (NURECA) listed?
Which sector does Nureca Ltd belong to?
What is the market capitalisation of Nureca Ltd?
What is the PE ratio of Nureca Ltd?
What is the 52-week high and low of Nureca Ltd?
Does Nureca Ltd pay dividends?
What is the Return on Equity (ROE) of Nureca Ltd?
Company Information
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NURECA.md for Nureca Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.